CA2722365C - Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging - Google Patents

Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging Download PDF

Info

Publication number
CA2722365C
CA2722365C CA2722365A CA2722365A CA2722365C CA 2722365 C CA2722365 C CA 2722365C CA 2722365 A CA2722365 A CA 2722365A CA 2722365 A CA2722365 A CA 2722365A CA 2722365 C CA2722365 C CA 2722365C
Authority
CA
Canada
Prior art keywords
chemotherapy
cells
mice
animal
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2722365A
Other languages
English (en)
French (fr)
Other versions
CA2722365A1 (en
Inventor
Valter Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Priority to CA3045883A priority Critical patent/CA3045883C/en
Publication of CA2722365A1 publication Critical patent/CA2722365A1/en
Application granted granted Critical
Publication of CA2722365C publication Critical patent/CA2722365C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2722365A 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging Active CA2722365C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3045883A CA3045883C (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4768008P 2008-04-24 2008-04-24
US61/047,680 2008-04-24
PCT/US2009/041736 WO2009132320A2 (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3045883A Division CA3045883C (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Publications (2)

Publication Number Publication Date
CA2722365A1 CA2722365A1 (en) 2009-10-29
CA2722365C true CA2722365C (en) 2019-08-06

Family

ID=41217444

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2722365A Active CA2722365C (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
CA3045883A Active CA3045883C (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3045883A Active CA3045883C (en) 2008-04-24 2009-04-24 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging

Country Status (5)

Country Link
EP (1) EP2285218B1 (cg-RX-API-DMAC7.html)
JP (2) JP2011523626A (cg-RX-API-DMAC7.html)
CA (2) CA2722365C (cg-RX-API-DMAC7.html)
ES (1) ES2800327T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009132320A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111790A1 (ja) * 2011-02-17 2012-08-23 味の素株式会社 化学療法剤の抗腫瘍活性増強剤
JP5752980B2 (ja) * 2011-04-04 2015-07-22 日本メジフィジックス株式会社 腎臓トランスポーターの輸送能を抑制するための組成物
CA2900782C (en) * 2013-02-12 2022-09-27 University Of Southern California Methods and diets to protect against chemotoxicity and age related illnesses
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用
EP3115047B1 (en) * 2014-03-07 2020-05-06 Ajinomoto Co., Inc. Debility preventative
EP3291693A4 (en) * 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
CN112752575A (zh) * 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
WO2021123245A1 (en) 2019-12-19 2021-06-24 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age-related medical conditions
AU2020468941A1 (en) * 2020-09-23 2023-03-23 Aminovita S.L. Metabolic cancer therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4574085A (en) * 1981-05-15 1986-03-04 Baxter Travenol Laboratories, Inc. Method for using dialysis solution containing glycerol
FR2591893B1 (fr) 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
FR2673812B1 (fr) * 1991-03-13 1994-04-01 Roussel Uclaf Nouvelles compositions destinees a etre utilisees en dietetique et en therapeutique et renfermant une combinaison particuliere de glucides et leurs applications.
JPH04352720A (ja) * 1991-05-30 1992-12-07 Tanabe Seiyaku Co Ltd 癌患者用アミノ酸製剤
WO1993006834A1 (en) * 1991-10-07 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Enteral preparation for cancer therapy
JP3380287B2 (ja) * 1992-04-07 2003-02-24 麒麟麦酒株式会社 血中アルコール濃度上昇阻害飲料
US6338856B1 (en) * 1998-02-27 2002-01-15 Texas Tech University Seaweed supplement diet for enhancing immune response in mammals and poultry
JPH11332514A (ja) * 1998-05-22 1999-12-07 Nof Corp バランス栄養食品
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
GB0416493D0 (en) * 2004-07-23 2004-08-25 Pitsiladis Yannis P Hydrating composition
EP1731145A1 (en) * 2005-05-25 2006-12-13 Institut National De La Recherche Agronomique Use of glycerol for improving cardiac function
EP2135604A4 (en) 2007-03-26 2011-08-03 Hirofumi Matsui PREPARATION OF INFUSION FOR PATIENT SUFFERING FROM CANCER

Also Published As

Publication number Publication date
WO2009132320A2 (en) 2009-10-29
JP2011523626A (ja) 2011-08-18
EP2285218B1 (en) 2020-06-17
JP2015186480A (ja) 2015-10-29
ES2800327T3 (es) 2020-12-29
CA3045883A1 (en) 2009-10-29
EP2285218A4 (en) 2011-10-05
EP2285218A2 (en) 2011-02-23
CA2722365A1 (en) 2009-10-29
WO2009132320A3 (en) 2010-01-07
CA3045883C (en) 2022-06-28

Similar Documents

Publication Publication Date Title
US8865646B2 (en) Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
CA3045883C (en) Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
Zhang et al. Akt activation: A potential strategy to ameliorate insulin resistance
Altea‐Manzano et al. Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Brandhorst et al. Fasting and caloric restriction in cancer prevention and treatment
Apostolova et al. Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets
Lee et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index
Casirola et al. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice
Nicastro et al. An overview of the therapeutic effects of leucine supplementation on skeletal muscle under atrophic conditions
ES2822178T3 (es) Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
Zhou et al. Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway
US20080038321A1 (en) Prophylactic/therapeutic compositions for liver diseases
US12472159B2 (en) Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
Zhao et al. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
BR112020009552A2 (pt) combinação farmacêutica de inibidor da via de sinalização do receptor de andrógeno e de inibidor de p38 para uso no tratamento de câncer de próstata e uso de um inibidor de p38 para restaurar a sensibilidade à adt
Ju et al. Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC
Hamers et al. Trametinib alters contractility of paediatric Noonan syndrome-associated hypertrophic myocardial tissue slices
Wojcik et al. Melatonin as a pleiotropic molecule with therapeutic potential for type 2 diabetes and cancer
Teixeira et al. Mitochondria-targeted ROS scavenger JP4-039 improves cardiac function in a post-myocardial infarction animal model and induces angiogenesis in vitro
Moreira et al. Mitochondria as potential targets in antidiabetic therapy
Zhang et al. High-iron diet damages brown adipose tissue mitochondria and exacerbates metabolic hazards of a high-fat diet
KR20120058047A (ko) 스핑고신-1-포스페이트(sphingosine-1-phosphate) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물
AU2005226731A1 (en) Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
Lee Fasting-based differential stress resistance to enhance cancer treatment: A novel strategy to protect normal cells and sensitize cancer cells to chemotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140423